Find
News Releases
= add release to Briefcase
| All Releases | |||
|---|---|---|---|
 |
Johnson & Johnson Consumer France SAS to Acquire Groupe Vendome SA Mar 23, 2006 |
7.2 KB |
|
|
ISSY-LES-MOULINEAUX, France, March 23, 2006 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Consumer France SAS said it has entered into an agreement to acquire Groupe Vendome, a privately held French marketer of adult and baby skin care products. This acquisition is subject to certain closing conditions and regulatory approvals, and... |
|||
|
Increased Use of Computers, Portable Gadgets Leading to More Visual Fatigue And Discomfort Mar 20, 2006 |
11.8 KB |
|
|
JACKSONVILLE, Fla., March 20, 2006 /PRNewswire via COMTEX News Network/ -- Studies have found that the majority of people who work at a computer experience some eye or vision problems, and that the level of discomfort appears to increase with the amount of computer use. But, increased use of smaller, portable work and recreational gadgets such as P... |
|||
|
Johnson & Johnson Announces Stock Repurchase Program Mar 8, 2006 |
5.9 KB |
|
|
Mar 08, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced that its Board of Directors has approved a stock repurchase program, authorizing the Company to buy back up to $5 billion of the corporation's common stock. Repurchases will take place on the open market from time to time based on market conditions. Th... |
|||
|
Johnson & Johnson To Participate In The 26th Annual Cowen & Company Health Care Conference Mar 1, 2006 |
5.6 KB |
|
|
Mar 01, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will participate in the 26th annual Cowen & Company Health Care Conference at The Boston Marriott Copley Place Hotel in Boston, Massachusetts on Tuesday, March 7, 2006. A Company presentation will be made by Louise Mehrotra and Stan Panasewicz of Investor Relations. ... |
|||
|
Silver Medalists Belbin & Agosto See Gold With ACUVUE® OASYS™ Brand Feb 23, 2006 |
9.9 KB |
|
|
JACKSONVILLE, Fla., Feb 23, 2006 /PRNewswire via COMTEX News Network/ -- VISTAKON®, a division of Johnson & Johnson Vision Care, Inc., today announced that its ACUVUE® OASYS™ Brand Contact Lenses with HYDRACLEAR™ PLUS will sponsor Olympic Silver medal winners Tanith Belbin and Ben Agosto throughout 2006. Belbin and Agost... |
|||
|
Johnson & Johnson Completes Acquisition of Animas Corporation Feb 17, 2006 |
5.6 KB |
|
|
Feb 17, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced the completion of its previously announced acquisition of Animas Corporation, an insulin delivery company. Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider... |
|||
|
Charles Prince of Citigroup Elected to Johnson & Johnson Board of Directors Feb 13, 2006 |
6.0 KB |
|
|
NEW BRUNSWICK, N.J., Feb 13, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Charles Prince, Chief Executive Officer of Citigroup, today was elected to the Board of Directors of Johnson & Johnson (NYSE: JNJ), the world's most broadly based health care products company. In his capacity as Chief Executive Officer, Mr. Prince serves... |
|||
|
Johnson & Johnson to Participate in Merrill Lynch Conference Feb 1, 2006 |
5.6 KB |
|
|
Feb 01, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will participate in The Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Devices Conference 2006: "Innovation Meets Economics." The conference is being held at the Grand Hyatt hotel in New York City. William C. Weldon, Chairman and Chief Executive Officer ... |
|||
|
European Commission Approves IONSYS(TM) (Fentanyl HCl Iontophoretic Transdermal System) Jan 30, 2006 |
7.8 KB |
|
|
MOUNTAIN VIEW, Calif., Jan 30, 2006 /PRNewswire via COMTEX News Network/ -- The European Commission has granted marketing authorization in the 25 member states of the European Union for the use of IONSYS(TM) (Fentanyl hydrochloride (HCl) Iontophoretic Transdermal System (ITS) 40 mcg/dose). IONSYS is the first needle-free, iontophoretic, patient-co... |
|||
|
Johnson & Johnson Statement Regarding Guidant Corporation Jan 25, 2006 |
5.6 KB |
|
|
Jan 25, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson acknowledged that it has been notified by Guidant Corporation that Guidant has terminated the companies' existing acquisition agreement. Johnson & Johnson said that it had determined not to increase its last offer for Guidant Corporation, because to do so would not ha... |
|||
|
Johnson & Johnson Reports Full-Year and Fourth-Quarter 2005 Results Jan 24, 2006 |
18.3 KB |
|
|
Jan 24, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced sales for the fourth quarter of $12.6 billion, a decline of 1.1% as compared to the fourth quarter of 2004. Operational growth was .7% with a negative currency impact of 1.8%. Domestic sales were down 4.2%, while international sales increased 3.1%, ref... |
|||
|
DePuy Orthopaedics Concludes Acquisition of Hand Innovations LLC Jan 19, 2006 |
6.7 KB |
|
|
WARSAW, Ind., Jan 19, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- DePuy Orthopaedics, Inc. today announced the acquisition of Hand Innovations LLC, a privately held manufacturer of widely used fracture fixation products for the upper extremities. The acquisition provides DePuy Orthopaedics with leading technology in the plating business... |
|||
|
Johnson & Johnson to Review Fourth-Quarter and Full-Year 2005 Financial Results Jan 18, 2006 |
5.9 KB |
|
|
NEW BRUNSWICK, N.J., Jan 18, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will hold a meeting for financial analysts at 8:30 a.m. ET on Tuesday, January 24, 2006 to review fourth-quarter and full-year 2005 financial results. William C. Weldon, Chairman and Chief Executive Officer, will host the meeting. Investor... |
|||
|
Johnson & Johnson Statement Regarding Guidant Corporation Acquisition Jan 17, 2006 |
7.7 KB |
|
|
Jan 17, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson said it has received notice from the Guidant board of directors that the acquisition proposal received today from Boston Scientific constitutes a superior proposal. Johnson & Johnson considers the proposal from Boston Scientific to be a highly dilutive and leveraged t... |
|||
|
Guidant Corporation and Johnson & Johnson Announce New Definitive Acquisition Agreement Jan 13, 2006 |
9.8 KB |
|
|
INDIANAPOLIS and NEW BRUNSWICK, N.J., Jan 13, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Guidant Corporation (NYSE: GDT) and Johnson & Johnson (NYSE: JNJ) today announced that they have reached a new agreement whereby Johnson & Johnson will acquire Guidant for $24.2 billion in fully diluted equity value. The boards of directors of both... |
|||
|
Guidant Corporation and Johnson & Johnson Announce New Definitive Acquisition Agreement Jan 11, 2006 |
9.9 KB |
|
|
INDIANAPOLIS and NEW BRUNSWICK, N.J., Jan 11, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Guidant Corporation (NYSE: GDT) and Johnson & Johnson (NYSE: JNJ) today announced that they have reached a new agreement whereby Johnson & Johnson will acquire Guidant for $23.2 billion in fully diluted equity value. The boards of directors of both... |
|||
|
Johnson & Johnson Reaffirms Commitment to Guidant Acquisition Jan 8, 2006 |
8.6 KB |
|
|
NEW BRUNSWICK, N.J., Jan 08, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson reaffirmed today that it expects to consummate the acquisition of Guidant Corporation immediately following a favorable shareholder vote by Guidant shareholders on January 31. All other conditions to close have been satisfied. "We continue to ... |
|||
|
Scios Submits Interim Report to FDA on NATRECOR®(nesiritide) PROACTION Trial Jan 3, 2006 |
10.8 KB |
|
|
FREMONT, Calif., Jan 03, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Scios Inc. today announced it is submitting an interim report to the U.S. Food & Drug Administration, and other relevant international regulatory authorities, on an ongoing expanded analysis of a three-year-old exploratory health outcomes study (the PROACTION trial... |
|||
= add release to Briefcase
